Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Discover the power of Pharma360

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

View all content

Biomedtracker

Biopharma Partnering and Financing Trends, H1 2020 Whitepaper

Get an inside view into the trends powering COVID-era deal making in the life sciences with your free copy of “Biopharma Partnering and Financing Trends, H1 2020”. Informa Pharma Intelligence takes you inside the forces shaping the industry

Topic BIO-Europe

View white paper
Scrip

Five Phase III Data Readouts To Look Out For In Q2

Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.

View article
Scrip

Shifting Research Realities After COVID-19 Place Decentralized Trials Center Stage

Agreeing that decentralized trials are here to stay, experts discussed in a recent meeting ways in which the pharma research landscape is set to change. With nearly 85% of the industry at different stages of adoption, such trials have seen greater traction in the US, while stricter data privacy laws have hampered progress in Europe, ISCR’s annual conference heard.

View article
Scrip

Scrip Asia 100 Report Extract

Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.

Topic Business Strategies China Company Analysis Drug Development Landscape Market Intelligence

Single report
Scrip

Dunad Makes Debut In Protein Degradation Space

Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer’s, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca’s coronavirus vaccine, and a Scrip roundtable on industry lessons from the pandemic.

View article
Biomedtracker, Scrip

39th Annual J.P. Morgan Healthcare Conference 2021

Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.

View analysis
Scrip

Moderna Not Immune To COVID-19 Effects On Trials

Company suspends enrolment to trials as coronavirus travel restrictions bite.

Topic Coronavirus

View article
Scrip

Pandemic Perspectives: R&D Lessons Learned From The COVID Year

The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.

View article
Scrip

AstraZeneca’s COVID-19 Vaccine PR Nightmare Won’t Faze Investors

Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.

View article
Scrip

Coronavirus Update: How Vaccines Stack Up Against Variants So Far

Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.

View article
Scrip

Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition

Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.

View article
Scrip

‘Reckless’ State Campaigns Seek To Undermine Western COVID-19 Vaccines

China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.

View article
Biomedtracker

2021 Clinical Development Success Rates

This is both an updated study of clinical drug development success rates from our 2016 report, and an expansion into the drivers of success with the addition of machine learning modeling to analyze the predictive factors contributing to drug development.

Topic Clinical Trials Drug Development Landscape Drug Pricing

View white paper